welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)
study id #: NCT00140894
condition: Adenomatous Polyposis Coli
A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.
Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks
Drug: Comparator: placebo / Duration of Treatment: 24 weeks
start date: March 2003
estimated completion: Not Available
last updated: August 23, 2015
phase of development: Phase 4
size / enrollment: 62
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
- Number and average size of rectal polyps
- Safety and tolerability
- Number and average size of duodenal polyps
- Proportions of patients with improved overall colon rating
- Males or females at least 18 years of age with familial adenomatous polyposis.
expertly curated content related to this topic
Detection of Epithelial Apoptosis in Pelvic Ileal Pouches for Ulcerative Colitis and Familial Adenomatous PolyposisBACKGROUND : Ileal pouch-anal anastomosi...
Papa's Got A Brand New Bag!I miss you, I need you, and I’m scared...
Familial Adenomatous Polyposis in Pediatrics: Natural History, Emerging Surveillance and Management Protocols, Chemo...Familial adenomatous polyposis (FAP) is ...
Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adj...Colorectal cancer (CRC) is a leading cau...
If you have a few small polyps, your May...
Discerning the genetics of hereditary co...
This chapter briefly summarizes the curr...